Flu activity spikes early and a new mRNA vaccine shows promise for seniors

Influenza monitoring shows an unusually early increase in cases, with wastewater analyses revealing activity comparable to the December-January peak period, although the majority of regions remain in a minimal-case category. The CDC emphasizes that flu seasons vary and that current trends still fall within expected seasonal variation, noting the early rise began in western states such as California, Washington, Hawaii and Alaska.

In August, the FDA approved mFLUSIVA, the first mRNA-based flu vaccine targeting adults 50 and older, which instructs immune cells via mRNA rather than using a weakened virus. Early studies report a 27% lower infection rate in this age group compared with traditional shots, with side-effect profiles similar to existing vaccines. Health experts advise that all individuals six months and older receive an annual flu vaccine, and that seniors, particularly those with chronic health issues, consider the new mRNA option when available, while still opting for the conventional vaccine if the newer one is inaccessible.